{"filing":{"accession_number":"0001654954-26-008172","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"a8764t.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426008172/a8764t.htm"},"events":[{"id":31866,"run_id":29265,"accession_number":"0001654954-26-008172","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This 6-K furnishes a press release announcing positive Phase III trial results for Imfinzi plus Imdelltra in small cell lung cancer, demonstrating \"statistically significant and highly clinically meaningful improvement in overall survival\" versus Imfinzi alone. While technically a clinical trial result rather than financial earnings, this disclosure functions as a material product/pipeline announcement that would affect investor assessment of AstraZeneca's oncology portfolio and commercial prospects. The language emphasizing \"unprecedented improvement\" and \"new standards of care\" signals material clinical and commercial significance.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":34892,"accession_number":"0001654954-26-008172","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This 6-K furnishes a press release announcing positive Phase III trial results for Imfinzi plus Imdelltra in small cell lung cancer, demonstrating \"statistically significant and highly clinically meaningful improvement in overall survival\" versus Imfinzi alone. While technically a clinical trial result rather than financial earnings, this disclosure functions as a material product/pipeline announcement that would affect investor assessment of AstraZeneca's oncology portfolio and commercial prospects. The language emphasizing \"unprecedented improvement\" and \"new standards of care\" signals material clinical and commercial significance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:05:47.419869+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-08"}]}